Table 3.

Predictive capacity following the consecutive addition of biomarkers to clinical variables.

Models	DFS					OS
	AIC	LLR†	P†	LLR‡	P‡	AIC	LLR†	P†	LLR‡	P‡
Model 1 pCR + HR/HER2 status	79	22.50	<0.001	15.46	<0.001	70	20.69	<0.001	10.71	0.005
Model 2 + NLR + TILs	68	7.04	0.030	ref	n/a	64	9.98	0.007	ref	n/a
Model 3 +AURKA + MYBL2	64	ref	n/a	n/a	n/a	58	ref	n/a	n/a	n/a

†Likelihood ratio test (LLRT) and p value for comparison of model 3 (reference category) and models 1 and 2 (nested models).

‡ Likelihood ratio test (LLRT) and p value for comparison of model 2 (reference category) and model 1 (nested model).

AIC, Akaike Information Criterion; AURKA, Aurora kinase A; DFS, disease-free survival; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NLR, neutrophil-to-lymphocyte ratio; MYBL2, MYB Proto-Oncogene Like 2; OS, overall survival; pCR, pathological complete response; TILs, tumor-infiltrating lymphocytes; Ref, reference; N/a, not applicable.